Prepulse inhibition in an auditory discrimination: Effects of neuroleptic treatment on ERPs in schizophrenic patients

1997 ◽  
Vol 42 (1) ◽  
pp. 187S
Author(s):  
U. Schall ◽  
S. Bender ◽  
J. Wolstein ◽  
I. Grzella ◽  
M. Butorac ◽  
...  
Keyword(s):  
Prepulse Inhibition ◽  
Auditory Discrimination ◽  
Neuroleptic Treatment ◽  
Schizophrenic Patients

Immune modulation in resistant schizophrenic patients during long-term neuroleptic treatment

1997 ◽  
Vol 42 (1) ◽  
pp. 108S
Author(s):  
S. Bignotti ◽  
G.B. Tura ◽  
G. Rossi ◽  
R. Pioli ◽  
M. Maes ◽  
...  
Keyword(s):  
Immune Modulation ◽  
Neuroleptic Treatment ◽  
Schizophrenic Patients

scholarly journals Use of a modified prepulse inhibition paradigm to assess complex auditory discrimination in rodents

2008 ◽  
Vol 76 (1-2) ◽  
pp. 1-7 ◽  
Author(s):  
R. Holly Fitch ◽  
Steven W. Threlkeld ◽  
Melissa M. McClure ◽  
Ann M. Peiffer
Keyword(s):  
Prepulse Inhibition ◽  
Auditory Discrimination

Serum immunoglobulins in tardive dyskinesia — implication for pathogenesis of the syndrome

1990 ◽  
Vol 7 (2) ◽  
pp. 145-146 ◽  
Author(s):  
Hanafy Youssef
Keyword(s):  
Tardive Dyskinesia ◽  
Serum Immunoglobulin ◽  
Neuroleptic Treatment ◽  
Serum Immunoglobulins ◽  
Schizophrenic Patients ◽  
Immunological System

AbstractLevels of immunoglobulins were measured in 32 schizophrenic patients with tardive dyskinesia and 34 schizophrenic patients without tardive dyskinesia. The duration of neuroleptic treatment in years was similar in the two groups. The serum immunoglobulin concentrations (mg%) were found to be significantly different in the two groups; IGA and IGM levels were higher in patients with tardive dyskinesia. The present results may be explained on the basis of dysfunction of the immunological system in tardive dyskinesia.

Relevance of the dopamine D2 receptor blockade in clinical response to neuroleptic treatment in schizophrenic patients

1989 ◽  
Vol 2 (1-2) ◽  
pp. 207
Author(s):  
Ana Hitri ◽  
Parvathi Mohan ◽  
Dharmber Sinha ◽  
James Harrold ◽  
BruceI. Diamond ◽  
...  
Keyword(s):  
Clinical Response ◽  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
Receptor Blockade ◽  
Neuroleptic Treatment ◽  
Dopamine D2 ◽  
Schizophrenic Patients

Therapy monitoring with prepulse inhibition in an active auditory discrimination in patients with schizophrenia

1996 ◽  
Vol 18 (2-3) ◽  
pp. 224 ◽  
Author(s):  
S. Bender ◽  
J. Wolstein ◽  
M. Butorac ◽  
I. Grzella ◽  
K. Ortmann ◽  
...  
Keyword(s):  
Prepulse Inhibition ◽  
Therapy Monitoring ◽  
Auditory Discrimination

Low CSF Concentrations of Cyclic GMP in Schizophrenia

1983 ◽  
Vol 142 (3) ◽  
pp. 288-291 ◽  
Author(s):  
W. F. Gattaz ◽  
H. Cramer ◽  
H. Beckmann
Keyword(s):  
Cerebrospinal Fluid ◽  
Cyclic Gmp ◽  
Homovanillic Acid ◽  
Healthy Controls ◽  
Neuroleptic Treatment ◽  
Cholinergic Activity ◽  
Schizophrenic Patients ◽  
Csf Levels

SummaryIncreasing evidence suggests that the concentrations of cyclic guanosine 3′5′-monophosphate (cGMP) in the cerebrospinal fluid (CSF) may reflect central cholinergic activity. When the concentrations of this nucleotide in the CSF from 28 schizophrenic patients (13 without and 15 with neuroleptic treatment) and 16 psychiatrically healthy controls was determined the schizophrenics showed significantly lower CSF levels of cGMP as compared to controls.As dopamine and homovanillic acid concentrations were not altered in these CSF samples, this finding of reduced cGMP suggests a cholinergic-dopaminergic imbalance in schizophrenia, with a reduction of the former and consequently a relative dominance of the latter.

Sign in / Sign up

Export Citation Format

Share Document